

Final Appraisal Recommendation

Advice No: 1716 – July 2016

Ceftolozane/tazobactam (Zerbaxa[®]▼) 1.0 g/0.5 g powder for concentrate for solution for infusion

Submission by Merck Sharp & Dohme Ltd

Recommendation of AWMSG

Ceftolozane/tazobactam (Zerbaxa[®]▼) is recommended as an option for restricted use within NHS Wales for the treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; and complicated urinary tract infections.

Ceftolozane/tazobactam (Zerbaxa[®]▼) is recommended only following non responsive first line therapy due to resistance, i.e. where susceptibility has been confirmed and ceftolozane/tazobactam (Zerbaxa[®]▼) is considered the most clinically appropriate option following Consultant Microbiologist advice.

Ceftolozane/tazobactam (Zerbaxa[®]▼) is not recommended for use within NHS Wales outside of this subgroup of patients.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2356), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Merck Sharp & Dohme Limited
Date of first issue	July 2016
Last reviewed	July 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1716:
Ceftolozane/tazobactam (Zerbaxa[®]) 1.0 g/0.5 g powder for concentrate for solution for infusion.
July 2016.

